SEND Blog

AcademicBiotechCROPharmaceuticalPre-ClinicalSafety PharmacologySENDSEND Advantage ServicesSensible SENDStudy Management

Webinar Recap: When SEND Quality Matters Most

Instem Team

Our recent webinar, “When SEND Quality Matters Most”, explored the recent FDA communications regarding data quality, why regulatory expectations are shifting, where common issues arise, and how organizations can strengthen confidence before filing SEND datasets...

AgencyArtificial Intelligence and Machine LearningClimbCompany NewsCROPharmaceuticalPre-ClinicalProvantisRegulatory ComplianceRegulatory SubmissionsSENDSEND Advantage ServicesStudy ManagementSubmit

Instem Interact 2026 – A Resounding Success

Instem Team

Turning Insight into Innovation in Preclinical R&D

Regulatory ComplianceRegulatory SubmissionRegulatory SubmissionsSENDSensible SEND

What the FDA Webcast Revealed About SEND (and Why It Matters)

Marc Ellison

“For the first time, the FDA openly acknowledged that they are rejecting some SEND datasets because the quality isn’t good enough. No ambiguity. Just a clear statement that quality matters, and that poor SEND has...

BiotechCROPharmaceuticalPre-ClinicalResourcesSENDSEND Advantage ServicesToxicology

White Paper: Preparing Your Team for SEND 4.0

Instem Team

SEND 4.0 introduces one of the most significant updates to nonclinical data standards, expanding scientific coverage and modernizing core structures across the SEND ecosystem. This white paper outlines the key changes such as new domains,...

Regulatory ComplianceRegulatory SubmissionRegulatory SubmissionsSENDSensible SEND

An Easy Guide to Reviewing SEND v4.0

Marc Ellison

SEND Implementation Guide v4.0 is the biggest change I’ve seen to the standard in the 15 years I’ve been involved. Here’s what you need to know.

Stay up to Date

Get expert tips, industry news, and fresh content delivered to your inbox.